The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain

Brain Research

Volumn 1354, Issue , 2010, Pages 236-242

  Bukhatwa, Salma ^a   Zeng, Bai Yun ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dose; Parkinson's disease; Proteasome; PSI; Route

Indexed keywords

BENZYLOXYCARBONYL ISOLEUCYL GLUTAMYL(O TERT BUTYL)ALANYL LEUCINAL; NEUROPROTECTIVE AGENT; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LOCUS CERULEUS; MEYNERT BASAL NUCLEUS; MOTOR ACTIVITY; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAPHE NUCLEUS; RAT; SUBSTANTIA NIGRA; VAGUS NERVE;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MOTOR ACTIVITY; NERVE DEGENERATION; NEURONS; OLIGOPEPTIDES; RATS; RATS, WISTAR; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 77956396475     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.07.060     Document Type: Article

References (21)

1. J. Bove, C. Zhou, V. Jackson-Lewis, J. Taylor, Y. Chu, H. Rideout, D. Wu, J. Kordower, L. Petrucelli, and S. Przedborski Proteasome inhibition and Parkinson's disease modelling Ann. Neurol. 60 2006 260 264
2. H. Braak, E. Ghebremedhin, U. Rüb, H. Bratzke, and K. Del Tredici Stages in the development of Parkinson's disease-related pathology Cell Tissue Res. 318 2004 121 134
3. H. Braak, K. Del Tredici, U. Rüb, R.A. de Vos, E.N. Jansen Steur, and E. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211
4. S. Bukhatwa, M.M. Iravani, B.Y. Zeng, J.D. Cooper, S. Rose, and P. Jenner An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat J. Neurochem. 109 2009 52 59
5. A.F. Kisselev, and A.L. Goldberg Proteasome inhibitors: from research tools to drug candidates Chem. Biol. 8 2001 739 758
6. J.H. Kordower, N.M. Kanaan, Y. Chu, R.S. Babu, J. Stansell, B.T. Terpstra, C.E. Sortwell, K.S. Collier, and T.J. Collier Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys Ann. Neurol. 60 2006 264 268
7. A. Manning-Bog, S. Reaney, V. Chou, L. Johnston, A. McCormack, J. Johnston, J. Langston, and D. DiMonte Lack of nigrostriatal pathology in a rat model of proteasome inhibition Ann. Neurol. 60 2006 256 260
8. K.S. McNaught, and P. Jenner Proteasomal function is impaired in substantia nigra in Parkinson's disease Neurosci. Lett. 297 2001 191 194
9. K.S. McNaught, L.M. Bjorklund, R. Belizaire, O. Isacson, P. Jenner, and C.W. Olanow Proteasome inhibition causes nigral degeneration with inclusion bodies in rats NeuroReport 13 2002 1437 1441
10. K.S. McNaught, C. Mytilineou, R. Jnobaptiste, J. Yabut, P. Shashidharan, P. Jenner, and C.W. Olanow Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures J. Neurochem. 81 2002 301 306
11. K.S. McNaught, D.P. Perl, A.L. Brownell, and C.W. Olanow Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease Ann. Neurol. 56 2004 149 162
12. K.S. McNaught, and C. Olanow Proteasome inhibitor-induced model of Parkinson's disease Ann. Neurol. 60 2006 243 247
13. H. Miwa, T. Kubo, A. Suzuki, and T. Kondo Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats Neurosci. Lett. 401 2006 146 149
14. V. Nair, K.S. McNaught, J. Gonzales-Maeso, S.C. Sealfon, and C.W. Olanow Proteasome inhibitors cause a progressive model of Parkinson's disease in mice Mov. Disord. 20 suppl 10 2005 LB-12
15. V.D. Nair, K.S. McNaught, J. Gonzalez-Maeso, S.C. Sealfon, and C.W. Olanow p53 Mediates non-transcriptional cell death in dopaminergic cells in response to proteasome inhibition J. Biol. Chem. 2006 M603950200
16. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1986 Academic Press New York
17. S.H. Reaney, L.C. Johnston, W.J. Langston, and D.A. Di Monte Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures Exp. Neurol. 202 2006 434 440
18. H.J. Rideout, K.E. Larsen, D. Sulzer, and L. Stefanis Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells J. Neurochem. 78 2001 899 908
19. A. Schapira, M. Cleeter, J. Muddle, J. Workman, J. Cooper, and R. King Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons Ann. Neurol. 60 2006 253 255
20. F. Sun, V. Anantharam, D. Zhang, C. Latchoumycandane, A. Kanthasamy, and A.G. Kanthasamy Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models Neurotoxicology 27 2006 807 815
21. B.Y. Zeng, S. Bukhatwa, A. Hikima, S. Rose, and P. Jenner Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats Ann. Neurol. 60 2006 248 252